A next-gen Covid-19 an­tivi­ral has flunked a Phase II test, forc­ing its de­vel­op­er to go in­to some se­ri­ous soul search­ing.  The mid-stage read­out was cru­cial … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas
 © Endpoints News 2024 If you're already an Endpoints subscriber, enter your email below for a
                                    magic link that lets you log in quickly without using a password. Please note the magic link is
                                    one-time use only and expires after 24 hours. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma 
ENDPOINTS NEWS Daily at 11:30 AM ET
 
EARLY EDITION Daily at 7:15 AM ET
 
ENDPOINTS PHARMA Daily at 3:30 PM ET
 
BREAKING NEWS ALERTS 2-3 times a week
 
ENDPOINTS FDA+ Wed at 2 PM ET
 
ENDPOINTS MANUFACTURING Thu at 2 PM ET
 
ENDPOINTS WEEKLY Sat at 6 AM ET
 
POST-HOC 1-2 times a week
 Healthcare 
ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET
 
BREAKING NEWS ALERTS 2-3 times a week
 Want unlimited access? Sign up for a premium subscription plan.